Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis

Fertil Steril. 2006 Dec;86(6):1716-22. doi: 10.1016/j.fertnstert.2006.05.052. Epub 2006 Oct 30.

Abstract

Objective: To investigate the association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of unexplained recurrent pregnancy loss (URPL).

Design: Meta-analysis of published case-control studies of the MTHFR C677T variant and URPL risk.

Setting: A research institution in China.

Patient(s): Women with URPL.

Intervention(s): None.

Main outcome measure(s): Odds ratios (ORs) and 95% confidence intervals (CIs) for TT versus CC genotype, CT versus CC genotype, TT versus CT and CC genotype combined, and for T versus C allele.

Result(s): Twenty-six studies with 2120 URPL cases and 2949 controls were included. Overall random-effects ORs of 1.49 (95% CI, 1.12-2.00) for TT versus CC genotype, 1.40 (95% CI, 1.11-1.77) for TT versus CT and CC genotype combined, and 1.21 (95%CI, 1.04-1.40) for T versus C allele were found. Stratified analysis showed that significant strong associations between MTHFR C677T polymorphism and URPL were present only in the five Chinese studies (OR = 2.96 for TT versus CC genotype; OR = 2.30 for TT versus CT+CC genotype; OR = 1.73 for T versus C allele), but not in any other studies, including the studies conducted in the European countries.

Conclusion(s): The MTHFR C677T mutation is not a genetic risk factor for URPL except in a Chinese population.

Publication types

  • Meta-Analysis

MeSH terms

  • Abortion, Habitual / epidemiology*
  • Abortion, Habitual / genetics*
  • Adult
  • China / epidemiology
  • Female
  • Genetic Predisposition to Disease / epidemiology
  • Genetic Predisposition to Disease / genetics
  • Genetic Testing / methods
  • Humans
  • Incidence
  • Internationality
  • MEDLINE*
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Polymorphism, Genetic
  • Pregnancy
  • Risk Assessment / methods*
  • Risk Factors

Substances

  • Methylenetetrahydrofolate Reductase (NADPH2)